Literature DB >> 29140568

CRISPR/Cas9-Based Safe-Harbor Gene Editing in Rhesus iPSCs.

Ravi Chandra Yada1, John W Ostrominski1, Ilker Tunc2, So Gun Hong1, Jizhong Zou3, Cynthia E Dunbar1.   

Abstract

NHP iPSCs provide a unique opportunity to test safety and efficacy of iPSC-derived therapies in clinically relevant NHP models. To monitor these cells in vivo, there is a need for safe and efficient labeling methods. Gene insertion into genomic safe harbors (GSHs) supports reliable transgene expression while minimizing the risk the modification poses to the host genome or target cell. Specifically, this protocol demonstrates targeting of the adeno-associated virus site 1 (AAVS1), one of the most widely used GSH loci in the human genome, with CRISPR/Cas9, allowing targeted marker or therapeutic gene insertion in rhesus macaque induced pluripotent stem cells (RhiPSCs). Furthermore, detailed instructions for screening targeted clones and a tool for assessing potential off-target nuclease activity are provided. © 2017 by John Wiley & Sons, Inc.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Keywords:  CRISPR/Cas9; Rhesus macaque; induced pluripotent stem cells; non-human primate; safe-harbor

Mesh:

Year:  2017        PMID: 29140568      PMCID: PMC5709051          DOI: 10.1002/cpsc.37

Source DB:  PubMed          Journal:  Curr Protoc Stem Cell Biol        ISSN: 1938-8969


  18 in total

1.  Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers.

Authors:  So Gun Hong; Ravi Chandra Yada; Kyujoo Choi; Arnaud Carpentier; T Jake Liang; Randall K Merling; Colin L Sweeney; Harry L Malech; Moonjung Jung; Marcus A F Corat; Aisha A AlJanahi; Yongshun Lin; Huimin Liu; Ilker Tunc; Xujing Wang; Maryknoll Palisoc; Stefania Pittaluga; Manfred Boehm; Thomas Winkler; Jizhong Zou; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

2.  Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.

Authors:  Randall K Merling; Colin L Sweeney; Uimook Choi; Suk See De Ravin; Timothy G Myers; Francisco Otaizo-Carrasquero; Jason Pan; Gilda Linton; Lifeng Chen; Sherry Koontz; Narda L Theobald; Harry L Malech
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

3.  Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting.

Authors:  Jizhong Zou; Colin L Sweeney; Bin-Kuan Chou; Uimook Choi; Jason Pan; Hongmei Wang; Sarah N Dowey; Linzhao Cheng; Harry L Malech
Journal:  Blood       Date:  2011-03-16       Impact factor: 22.113

4.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

5.  Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back.

Authors:  Byeong-Cheol Ahn
Journal:  Theranostics       Date:  2012-04-11       Impact factor: 11.556

6.  Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases.

Authors:  Seung Woo Cho; Sojung Kim; Yongsub Kim; Jiyeon Kweon; Heon Seok Kim; Sangsu Bae; Jin-Soo Kim
Journal:  Genome Res       Date:  2013-11-19       Impact factor: 9.043

7.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

8.  CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets.

Authors:  Shengdar Q Tsai; Nhu T Nguyen; Jose Malagon-Lopez; Ved V Topkar; Martin J Aryee; J Keith Joung
Journal:  Nat Methods       Date:  2017-05-01       Impact factor: 28.547

9.  CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity.

Authors:  Thomas J Cradick; Eli J Fine; Christopher J Antico; Gang Bao
Journal:  Nucleic Acids Res       Date:  2013-08-11       Impact factor: 16.971

Review 10.  Engineered Viruses as Genome Editing Devices.

Authors:  Xiaoyu Chen; Manuel A F V Gonçalves
Journal:  Mol Ther       Date:  2015-09-04       Impact factor: 11.454

View more
  4 in total

1.  Quantification of transgene expression in GSH AAVS1 with a novel CRISPR/Cas9-based approach reveals high transcriptional variation.

Authors:  Anne Inderbitzin; Tom Loosli; Roger D Kouyos; Karin J Metzner
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-09       Impact factor: 5.849

Review 2.  CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside.

Authors:  Olivier Humbert; Clare Samuelson; Hans-Peter Kiem
Journal:  Br J Haematol       Date:  2020-06-07       Impact factor: 6.998

3.  CRISPR/Cas9-mediated introduction of the sodium/iodide symporter gene enables noninvasive in vivo tracking of induced pluripotent stem cell-derived cardiomyocytes.

Authors:  John W Ostrominski; Ravi Chandra Yada; Noriko Sato; Michael Klein; Ksenia Blinova; Dakshesh Patel; Racquel Valadez; Maryknoll Palisoc; Stefania Pittaluga; Kah-Whye Peng; Hong San; Yongshun Lin; Falguni Basuli; Xiang Zhang; Rolf E Swenson; Mark Haigney; Peter L Choyke; Jizhong Zou; Manfred Boehm; So Gun Hong; Cynthia E Dunbar
Journal:  Stem Cells Transl Med       Date:  2020-07-23       Impact factor: 6.940

4.  Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the AAVS1 locus as not an entirely safe harbour.

Authors:  Jamie R Bhagwan; Emma Collins; Diogo Mosqueira; Mine Bakar; Benjamin B Johnson; Alexander Thompson; James G W Smith; Chris Denning
Journal:  F1000Res       Date:  2019-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.